Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
Pliant Therapeutics (Nasdaq: PLRX) announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024 in Vienna, Austria from September 7-11, 2024. The presentations focus on bexotegrast, a dual αVβ6/αVβ1 integrin inhibitor for treating fibrotic diseases.
Key presentations include:
- Evaluation of bexotegrast's antifibrotic activity in non-IPF interstitial lung disease
- Bexotegrast's effect on type 1 collagen deposition in IPF patients after 12 weeks
- Safety and tolerability of bexotegrast in Phase 2 trials for IPF and primary sclerosing cholangitis
- Post-hoc biomarker analysis in IPF patients receiving bexotegrast over 12 weeks
These presentations highlight Pliant's progress in developing novel therapeutics for fibrotic diseases, particularly idiopathic pulmonary fibrosis (IPF).
Pliant Therapeutics (Nasdaq: PLRX) ha annunciato quattro presentazioni imminenti al Congresso Internazionale della Società Europea di Respirazione (ERS) 2024 a Vienna, Austria, dal 7 all'11 settembre 2024. Le presentazioni si concentrano su bexotegrast, un inibitore duale degli integrin αVβ6/αVβ1 per il trattamento delle malattie fibrotiche.
Le presentazioni chiave includono:
- Valutazione dell'attività antifibrotica di bexotegrast nella malattia polmonare interstiziale non-IPF
- Effetto di bexotegrast sulla deposizione di collagene di tipo 1 nei pazienti con IPF dopo 12 settimane
- Sicurezza e tollerabilità di bexotegrast negli studi di Fase 2 per IPF e colangite sclerosante primaria
- Analisi post-hoc dei biomarcatori nei pazienti con IPF che ricevono bexotegrast per 12 settimane
Queste presentazioni evidenziano i progressi di Pliant nello sviluppo di terapie innovative per le malattie fibrotiche, in particolare la fibrosi polmonare idiopatica (IPF).
Pliant Therapeutics (Nasdaq: PLRX) anunció cuatro presentaciones próximas en el Congreso Internacional de la Sociedad Respiratoria Europea (ERS) 2024 en Viena, Austria, del 7 al 11 de septiembre de 2024. Las presentaciones se centran en bexotegrast, un inhibidor dual de integrinas αVβ6/αVβ1 para el tratamiento de enfermedades fibróticas.
Las presentaciones clave incluyen:
- Evaluación de la actividad antifibrótica de bexotegrast en enfermedad pulmonar intersticial no IPF
- Efecto de bexotegrast en la deposición de colágeno tipo 1 en pacientes con IPF después de 12 semanas
- Seguridad y tolerabilidad de bexotegrast en ensayos de Fase 2 para IPF y colangitis esclerosante primaria
- Análisis post-hoc de biomarcadores en pacientes con IPF que reciben bexotegrast durante 12 semanas
Estas presentaciones destacan el progreso de Pliant en el desarrollo de terapias novedosas para enfermedades fibróticas, especialmente la fibrosis pulmonar idiopática (IPF).
Pliant Therapeutics (Nasdaq: PLRX)는 2024년 9월 7일부터 11일까지 오스트리아 비엔나에서 열리는 유럽 호흡기학회 (ERS) 국제 학술 대회 2024에서의 네 가지 발표를 발표했습니다. 발표는 섬유증 질환 치료를 위한 이중 αVβ6/αVβ1 인테그린 억제제인 bexotegrast에 초점을 맞추고 있습니다.
주요 발표 내용은 다음과 같습니다:
- 비 IPF 간질성 폐질환에서의 bexotegrast의 항섬유증 활성을 평가
- 12주 후 IPF 환자에서의 bexotegrast의 1형 콜라겐 침착에 대한 효과
- IPF 및 원발성 경화성 담관염에 대한 제2상 시험에서의 bexotegrast의 안전성 및 내약성
- 12주 동안 bexotegrast를 받은 IPF 환자에서의 사후 생물표지자 분석
이 발표들은 Pliant이 섬유증 질환, 특히 특발성 폐섬유증 (IPF)에 대한 혁신적인 치료법 개발에서의 진행 상황을 강조합니다.
Pliant Therapeutics (Nasdaq: PLRX) a annoncé quatre présentations à venir lors du Congrès International de la Société Européenne de Respiration (ERS) 2024 à Vienne, Autriche, du 7 au 11 septembre 2024. Les présentations se concentrent sur bexotegrast, un inhibiteur d'intégrines αVβ6/αVβ1 pour le traitement des maladies fibrotiques.
Les présentations clés incluent :
- Évaluation de l'activité antifibrotique de bexotegrast dans les maladies pulmonaires interstitielles non-IPF
- Effet de bexotegrast sur la déposition de collagène de type 1 chez des patients atteints d'IPF après 12 semaines
- Sécurité et tolérabilité de bexotegrast dans les essais de phase 2 pour l'IPF et la cholangite sclérosante primaire
- Analyse post-hoc des biomarqueurs chez les patients atteints d'IPF recevant bexotegrast pendant 12 semaines
Ces présentations mettent en lumière les progrès de Pliant dans le développement de thérapies novatrices pour les maladies fibrosiques, en particulier la fibrose pulmonaire idiopathique (IPF).
Pliant Therapeutics (Nasdaq: PLRX) hat vier bevorstehende Präsentationen beim Europäischen Respiratorischen Gesellschaft (ERS) Internationalen Kongress 2024 in Wien, Österreich, vom 7. bis 11. September 2024, angekündigt. Die Präsentationen konzentrieren sich auf bexotegrast, einen dualen αVβ6/αVβ1 Integrinhemmer zur Behandlung von fibrotischen Erkrankungen.
Wichtige Präsentationen umfassen:
- Bewertung der antifibrotischen Aktivität von bexotegrast bei nicht-IPF interstitieller Lungenerkrankung
- Wirkung von bexotegrast auf die Ablagerung von Kollagen Typ 1 bei IPF-Patienten nach 12 Wochen
- Sicherheit und Verträglichkeit von bexotegrast in Phase-2-Studien bei IPF und primärer sklerosierender Cholangitis
- Post-hoc-Biomarkeranalyse bei IPF-Patienten, die 12 Wochen lang bexotegrast erhalten haben
Diese Präsentationen heben Pliants Fortschritte in der Entwicklung neuartiger Therapeutika für fibrotische Erkrankungen, insbesondere idiopathische pulmonale Fibrose (IPF), hervor.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced four upcoming presentations at the European Respiratory Society (ERS) International Congress 2024. The Congress will take place in Vienna, Austria from September 7 - 11, 2024.
Late Breaker - Oral and ePoster Presentations
Title: Evaluation of the antifibrotic activity of bexotegrast, a dual αVβ6/αVβ1 integrin inhibitor, in precision cut-lung slices prepared from non-IPF interstitial lung disease explants
Abstract: OA951
Presenter: Martin Decaris, Ph.D., Pliant Therapeutics
Date: Sunday, September 8, 2024
Session: Sarcoidosis: novel insights in disease epidemiology, immunology and treatment
Session Time: 9:30 a.m. – 10:45 a.m. CEST
Later Breaker - Oral and ePoster Presentations
Title: Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy
Abstract: OA1058
Presenter: Sydney B. Montesi, M.D., Massachusetts General Hospital, Havard Medical School
Date: Sunday, September 8, 2024
Session: Advances in clinical practice for rare interstitial diseases: from research to the real world
Session Time: 11:00 a.m. – 12:15 p.m. CEST
Oral and Poster Presentations
Title: Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
Abstract: OA2861
Presenter: Gregory Cosgrove, M.D., Pliant Therapeutics
Date: Monday, September 9, 2024
Session: Novel management strategies in pulmonary fibrosis
Session Time: 11:00 a.m. – 12:15 p.m. CEST
Poster Presentation
Title: Post-hoc biomarker analysis in participants with IPF receiving bexotegrast over 12-weeks in INTEGRIS-IPF
Abstract: PA4260
Presenter: Martin Decaris, Ph.D., Pliant Therapeutics
Date: Tuesday, September 10, 2024
Session: Pathogenesis of pulmonary fibrosis and serum biomarkers
Session Time: 8:00 a.m. – 9:30 a.m. CEST
Abstracts for select presentations are now available to registered attendees in the ERS International Congress 2023 Congress Programme.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases. Pliant's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. Bexotegrast has received Fast Track Designation and Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in IPF and PSC and Orphan Drug Designation from the European Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF, an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is conducting a Phase 1 study for its third clinical program, PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. In addition, Pliant has received regulatory clearance for the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com. Follow us on social media: X, LinkedIn, and Facebook.
Investor and Media Contact:
Christopher Keenan
Vice President, Investor Relations and Corporate Communications
Pliant Therapeutics, Inc.
ir@pliantrx.com
FAQ
What is Pliant Therapeutics (PLRX) presenting at the ERS International Congress 2024?
When and where is the European Respiratory Society (ERS) International Congress 2024 taking place?
What are the main topics of Pliant Therapeutics' (PLRX) presentations at the ERS Congress 2024?
Who are the presenters for Pliant Therapeutics' (PLRX) studies at the ERS Congress 2024?
What is bexotegrast, the drug being presented by Pliant Therapeutics (PLRX) at the ERS Congress 2024?
